The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006–2009) nationwide survey
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The aim of this study was to survey the 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) cancer screening program conducted in Japan.
The “FDG-PET cancer screening program” included both FDG-PET and positron emission tomography with computed tomography (PET/CT) with or without other combined screening tests that were performed for cancer screening in asymptomatic subjects. A total of 155,456 subjects who underwent the FDG-PET cancer screening program during 2006–2009 were analyzed.
Of the 155,456 subjects, positive findings suggesting possible cancer were noted in 16,955 (10.9 %). The number of cases with detected cancer was 1,912 (1.23 % of the total screened cases, annual range 1.14–1.30 %). Of the 1,912 cases of detected cancer, positive findings on FDG-PET were present in 1,491 cases (0.96 % of the total number of screened cases). According to the results of further examinations, the true positive rate for subjects with suggested possible cancer (positive predictive value) was 32.3 % with FDG-PET. Cancers of the colon/rectum, thyroid, lung, and breast were most frequently found (396, 353, 319, and 163 cases, respectively) with high PET sensitivity (85.9, 90.7, 86.8, 84.0 %, respectively). Prostate cancer and gastric cancer (165 and 124 cases, respectively) had low PET sensitivity (37.0 and 37.9 %, respectively). The Union for International Cancer Control (UICC) clinical stage of cancer found with the FDG-PET cancer screening program was mainly Stage I.
The FDG-PET screening program in Japan has detected a variety of cancers at an early stage. However, several cancers were found in repeated FDG-PET cancer screening program, indicating the limitation of a one-time FDG-PET cancer screening program. The value of the FDG-PET cancer screening program is left to the judgment of individuals with regard to its potentials and limitations.
- Schöder H, Gönen M. Screening for cancer with PET and PET/CT: potential and limitations. J Nucl Med. 2007;48(Suppl 1):4S–18S.
- Ide M. Cancer screening with FDG-PET. Q J Nucl Med Mol Imaging. 2006;50:23–7.
- Minamimoto R, Senda M, Uno K, Jinnouchi S, Iinuma T, Ito K, et al. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey. Ann Nucl Med. 2007;21:481–98. CrossRef
- Weckesser M, Schober O. Is whole-body FDG-PET valuable for health screening? Against. Eur J Nucl Med Mol Imaging. 2005;32:342–3. CrossRef
- Ide M, Suzuki Y. Is whole-body FDG-PET valuable for health screening? For. Eur J Nucl Med Mol Imaging. 2005;32:339–41. CrossRef
- Yasuda S, Ide M, Fujii H, Nakahara T, Mochizuki Y, Takahashi W, et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer. 2000;83:1607–11. CrossRef
- The Foundation for Promotion of Cancer Research (FPCR) Cancer Statistics in Japan 2010 http://ganjoho.jp/public/statistics/backnumber/2010_en.html.
- Ono K, Ochiai R, Yoshida T, Kitagawa M, Omagari J, Kobayashi H, et al. The detection rates and tumor clinical/pathological stages of whole-body FDG-PET cancer screening. Ann Nucl Med. 2007;21:65–72. CrossRef
- Kojima S, Zhou B, Teramukai S, Hara A, Kosaka N, Matsuo Y, et al. Cancer screening of healthy volunteers using whole-body F-18 FDG-PET scans: the Nishidai clinic study. Eur J Cancer. 2007;43:1842–8. CrossRef
- Nishizawa S, Kojima S, Teramukai S, Inubushi M, Kodama H, Maeda Y, et al. Prospective evaluation of whole-body cancer screening with multiple modalities including [18F]fluorodeoxyglucose positron emission tomography in a healthy population: a preliminary report. J Clin Oncol. 2009;27:1767–73. CrossRef
- Chen YK, Ding HJ, Su CT, Shen YY, Chen LK, Liao AC, et al. Application of PET and PET/CT imaging for cancer screening. Anticancer Res. 2004;24:4103–8.
- Ko DH, Choi JY, Song Y, Lee SJ, Kim YH, Lee K, et al. The usefulness of 18F-FDG PET as a cancer screening test. Nucl Med Mol Imaging. 2008;42:444–50.
- Lee JW, Kang KW, Paeng JC, Lee SM, Jang SJ, Chung JK, et al. Cancer screening using 18F-FDG PET/CT in Korean asymptomatic volunteers: a preliminary report. Ann Nucl Med. 2009;23:685–91. CrossRef
- Terauchi T, Murano T, Daisaki H, Kanou D, Shoda H, Kakinuma R, et al. Evaluation of whole-body cancer screening using 18F–2-deoxy-2-fluoro-d-glucose positron emission tomography: a preliminary report. Ann Nucl Med. 2008;22:379–85. CrossRef
- Minamimoto R, Senda M, Terauchi T, Jinnouchi S, Inoue T, Iinuma T, et al. Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey. Ann Nucl Med. 2011;25:45–54. CrossRef
- Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutch SM, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21–35. CrossRef
- Vach W, Flemming P, Hoilund-Carlsen PF, Gerke O, et al. Generating evidence for clinical benefit of PET/CT in diagnosing cancer patients. J Nucl Med. 2011;52:77S–85S. CrossRef
- Murano T, Minamimoto R, Senda M, Uno K, Jinnouchi S, Fukuda H, et al. Radiation exposure and risk-benefit analysis in cancer screening using FDG-PET: results of a Japanese nationwide survey. Ann Nucl Med. 2011;25:657–66. CrossRef
- Yasunaga H. Who wants cancer screening with PET? A contingent valuation survey in Japan. Eur J Radiol. 2009;70:190–4. CrossRef
- Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 2000;95:3053–63. CrossRef
- Chen CD, Yen MF, Wang WM, Wong JM, Chen TH. A case-cohort study for the disease natural history of adenomacarcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy. Br J Cancer. 2003;88:1866–73. CrossRef
- Prabhakar HB, Sahani DV, Fischman AJ, Mueller PR, Blake MA. Bowel hot spots at PET-CT. Radiographics. 2007;27:145–59. CrossRef
- Nakajo M, Jinnouchi S, Tashiro Y, Shirahama H, Sato E, Koriyama C, et al. Effect of clinicopathologic factors on visibility of colorectal polyps with FDG PET. AJR Am J Roentgenol. 2009;192:754–60. CrossRef
- The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006–2009) nationwide survey
Annals of Nuclear Medicine
Volume 27, Issue 1 , pp 46-57
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Cancer screening
- Industry Sectors
- Ryogo Minamimoto (1) (15)
- Michio Senda (2)
- Seishi Jinnouchi (3)
- Takashi Terauchi (4)
- Tsuyoshi Yoshida (5)
- Takeshi Murano (4)
- Hiroshi Fukuda (6)
- Takeshi Iinuma (7)
- Kimiichi Uno (8)
- Sadahiko Nishizawa (9)
- Eriko Tsukamoto (10)
- Hiroshi Iwata (11)
- Takeshi Inoue (12)
- Kazuhiro Oguchi (13)
- Rumi Nakashima (14)
- Tomio Inoue (15)
- Author Affiliations
- 1. Division of Nuclear Medicine, Department of Radiology, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjyuku-ku, Tokyo, 162-8655, Japan
- 15. Department of Radiology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
- 2. Division of Molecular Imaging, Institute of Biomedical Research and Innovation, Kobe, Japan
- 3. Atsuchi Memorial Institute of Radiology, Atsuchi Memorial Clinic PET Center, Kagoshima, Japan
- 4. Screening Technology and Development Division, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan
- 5. Department of Radiology, Koga Hospital 21 PET Center, Kurume, Japan
- 6. Department of Nuclear Medicine and Radiology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
- 7. National Institute of Radiological Sciences, Chiba, Japan
- 8. Gaien-higashi Clinic, Tokyo, Japan
- 9. Hamamatsu Medical Imaging Center, Hamamatsu Medical Photonics Foundation, Hamamatsu, Japan
- 10. Central CI Clinic, Sapporo, Japan
- 11. Department of Radiology, Nagoya PET Imaging Center, Nagoya, Japan
- 12. Department of Radiology, Ehime Prefectural Central Hospital, Matsuyama, Japan
- 13. Positron Imaging Center, Aizawa Hospital, Matsumoto, Japan
- 14. Japanese Red Cross Kumamoto Health Care Center, Kumamoto, Japan